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Meeting ReviewLipid Research Picks Up Speed
on the Slopes of Taos
are only now beginning to explore how lipid phospha-
tases are regulated, how they contribute to phosphoino-
sitide balance in cells, and how they affect cellular
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The importance of these questions is emphasized byDepartment of Cell Biology
Harvard Medical School the finding that defects in phosphoinositide phospha-
tases are directly linked to human disease. Cowden’s77 Avenue Louis Pasteur
Boston, Massachusetts 02115 and Bannayan-Zonana syndromes are caused by ge-
netic defects in the PTEN gene, and patients with2 Division of Endocrinology
Massachusetts General Hospital X-linked myotubular myopathy and type 4B Charcot-
Marie-Tooth syndrome carry mutations in the PtdIns(3)P55 Fruit Street
Boston, Massachusetts 02114 3-phosphatases MTM1 and MTMR2, respectively (Kim
et al., 2002). In his keynote address, Jack Dixon showed3 Boston Biomedical Research Institute
64 Grove Street that MTM1 and MTMR2 phosphatases have indistin-
guishable biochemical properties but that defects inWatertown, Massachusetts 02472
these two proteins nevertheless lead to different disease
syndromes. When overexpressed in COS cells, MTM1
and MTMR2 localize to different subcellular compart-The 2002 Keystone Symposium on “Regulation of Cel-
lular Responses by Lipid Mediators” provided a lively ments, suggesting that they may target different pools
of PtdIns(3)P. This could potentially explain their non-and active forum to discuss research in lipid signaling.
This meeting review can provide only a glimpse into overlapping physiological functions.
A number of talks and posters addressed the func-the diversity of research presented. Here we have cho-
sen to highlight a group of exciting presentations de- tions of SHIP and SHIP2, 5-phosphatases, which con-
vert PtdIns(3,4,5)P3 into PtdIns(3,4)P2. Christophe Er-scribing novel features of the temporal and spatial
regulation of phosphoinositides and their downstream neux presented his group’s work on SHIP2 knockout
mice, which clearly demonstrated that SHIP2 is an im-targets.
portant negative regulator of the insulin signal in animals
(Clement et al., 2001). Homozygous disruption of theThe Keystone Symposium on “Regulation of Cellular
SHIP2 gene causes severe hypoglycemia and neonatalResponses by Lipid Mediators” took place February 1–6,
lethality. Heterozygous disruption of this gene leads to2002, among the snow and the sagebrush of Taos, New
hypersensitivity to insulin and hypoglycemia. The mostMexico. Nearby Taos Ski Valley’s twisting and turning
straightforward explanation of these results is that losstrails provided a suitable backdrop for a meeting that
of SHIP2 reduces the rate of PtdIns(3,4,5)P3 turnover,supplied surprising and intriguing twists and turns in
leading to increased PtdIns(3,4,5)P3 levels in responseour understanding of the regulation of lipid signals and
to insulin receptor signaling, thus potentiating the ef-their role in diverse cellular processes. Like a skier se-
fects of insulin. Direct measurement of phosphoinositidelecting one of many paths down the mountain, our re-
levels may help support this likely model. In any case,view necessarily misses some of the thrills and vistas
these results identify SHIP2 as a potential drug targetof this vibrant meeting. We have chosen to focus this
in the treatment of diabetes mellitus.review on four topics that represent recurring themes
While it is clear that PtdIns(3,4,5)P3, the main substrateand/or particularly exciting new advances presented at
for SHIP2, is essential for Akt activation and, conse-the meeting. These include the following: (1) new in-
quently, insulin signaling, the role of PtdIns(3,4)P2, thesights into the function of phosphoinositide phospha-
product of SHIP and SHIP2, is still controversial. Twotases, their role in regulating downstream signaling
independent groups presented data suggesting thatevents, and their contribution to mammalian physiology,
PtdIns(3,4)P2 is a signaling molecule per se. Using bone(2) discoveries about the mechanisms by which changes
marrow-derived mast cells from wild-type or SHIPin phosphoinositides couple to the activation of small
knockout mice, Gerald Krystal showed that lack of SHIPG proteins such as Rac, (3) accumulating evidence hint-
leads to a dramatic increase in steel factor (SF)-induceding at a role for phosphoinositides in the nucleus, and
(4) broad interest in PI 3-kinase as a pharmaceutical PtdIns(3,4,5)P3 levels and a decrease in PtdIns(3,4)P2
target and the development of new PI 3-kinase assays levels, as would be expected from SHIP’s biochemical
amenable to high-throughput drug screens. activity (Scheid et al., 2002). His group found that by
treating SHIP/ cells with limited amounts of inhibitors
Phosphoinositide Phosphatases of PI 3-kinase, such as LY294002, they could reduce
In the past ten years, an overwhelming amount of infor- the PtdIns(3,4,5)P3 level to the level present in wild-type
mation regarding the regulation of phosphoinositide cells. This treatment also reduced PtdIns(3,4)P2 levels
synthesis by lipid kinases, mainly PI 3-kinase, has been to nearly undetectable. Thus, Dr. Krystal argued that
published in the literature (see Figure 1). However, we comparison of wild-type cells to LY294002-treated
SHIP/ cells could be used to determine the distinct
roles of PtdIns(3,4,5)P3 and PtdIns(3,4)P2 in downstream4 Correspondence: sfield@alum.mit.edu
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Figure 1. Schematic Depicting the Kinases
and Phosphatases that Interconvert the
Phosphoinositides
Kinases, red; phosphatases, black, blue, and
green. See text for details. (Artwork by K.A.L.)
signaling. This approach was used to establish a correla- product, each of which may have distinct downstream
targets. In this context, perhaps the SHIP proteins aretion between SF-stimulated phosphorylation of Akt at
Thr308 with PtdIns(3,4,5)P3 levels. In contrast, Akt phos- viewed best as a mechanism to simultaneously termi-
nate PtdIns(3,4,5)P3-initiated pathways and activatephorylation at Ser473 correlated with PtdIns(3,4)P2
levels. Introduction of exogenous PtdIns(3,4)P2 into PtdIns(3,4)P2-initiated pathways.
SHIP/ cells pretreated with PI 3-kinase inhibitors and
stimulated with SF led to increased Akt phosphorylation Interactions between Rac and Phosphoinositides
in Rufflingat Ser473 and activation. Dr. Krystal proposed that
PtdIns(3,4,5)P3 is essential for the recruitment of Akt to It has long been established that Rho family GTPases
are involved in stimulating actin reorganization in re-the membrane and for Thr308 phosphorylation by PDK1,
while PtdIns(3,4)P2 is necessary for accumulation of sponse to various growth factors. However, the precise
molecular links between receptor activation, small Gphosphorylation at Ser473 by regulation of either a ki-
nase or a phosphatase specific for this site. proteins, and the actin machinery remain somewhat
mysterious. A number of speakers presented evidenceAaron Marshall discussed two novel proteins, TAPP1
and TAPP2, that are potential targets for PtdIns(3,4)P2 for the involvement of phosphoinositides and the en-
zymes that produce them in these pathways.generated during B cell stimulation. These Bam32-
related proteins are expressed in many tissues but pre- Richard Anderson discussed work from his lab dem-
onstrating that phosphatidyl inositol 4-phosphatedominantly in lymphoid cells. Dowler et al. (2000) have
previously shown that TAPP1 and TAPP2 PH domains 5-kinase type I  (PIPKI) acts in concert with Rac to
stimulate actin reorganization. PIPKI producesbind specifically to PtdIns(3,4)P2. Dr. Marshall and col-
leagues expressed GFP-tagged TAPP1 and TAPP2 in PtdIns(4,5)P2, which many groups have shown to be
involved in actin polymerization. Dr. Anderson showedhuman B lymphoma cells as a probe for PtdIns(3,4)P2
and found that these proteins are recruited to actin-rich that microinjection of PIPKI induced actin reorganiza-
tion in cells that were PDGF stimulated but not in serummembrane ruffles through their PtdIns(3,4)P2 binding PH
domain in a PI 3-kinase-dependent manner. When com- starved cells. This effect was not blocked by inhibitors
of PI 3-kinase and was enhanced by inhibitors of pho-pared to other PH domains, TAPP1 and TAPP2 recruit-
ment to the membrane is delayed and sustained. The pholipase C, suggesting that the observed effects were
due to accumulation of PtdIns(4,5)P2 produced by theauthors hypothesize that TAPP1 and TAPP2 are targets
for PtdIns(3,4)P2 and may play a role in PI 3-kinase- microinjected enzyme. He also presented evidence that
both activated Rac and the PIPKI participate in anddependent cytoskeletal rearrangement.
We learned from Christina Mitchell’s presentation that are required for PDGF-stimulated membrane ruffle as-
sembly. Rac mutants that do not interact with PIPKISHIP2 is present in membrane ruffles and can associate
with the actin binding protein filamin (Dyson et al., 2001). poorly induce ruffling and do not show synergism with
PIPKI in PDGF-stimulated ruffle assembly. Further ex-Binding to filamin is mediated through the C-terminal
proline-rich domain of SHIP2 and may be an important periments will be necessary to demonstrate the precise
ordering of these enzymes in a biochemical pathwaymechanism to control the localization of SHIP2. SHIP2
could thereby regulate actin rearrangement by regulat- leading to growth factor-induced actin reorganization.
Lew Cantley presented genetic evidence for position-ing local levels of its substrate PtdIns(3,4,5)P3 or its prod-
uct PtdIns(3,4)P2 (or perhaps even the substrate ing PI 3-kinase upstream of Rac or other small G proteins
in signaling leading to the formation of lamellipodia. HePtdIns(4,5)P2).
The above studies underscore the concept articulated showed time-lapse video microscopy of mouse embry-
onic fibroblasts (MEFs) ruffling in response to PDGF.most clearly by Scott Emr that phosphoinositide kinases
and phosphatases always necessarily affect the levels MEFs lacking both isoforms of the regulatory subunit of
PI 3-kinase (p85 and p85) failed to ruffle in responseof two phosphoinositides, the enzyme’s substrate and
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to PDGF. However, unstimulated p85/;p85/MEFs group’s recent genetic data tying inositol polyphosphate
metabolism to mRNA export events on the cytoplasmicwill ruffle when they are made to express high levels of
Vav2, which is a GEF for Rho family small GTPases. face of the nuclear pore. As yet, there is no biochemical
data to provide a detailed mechanism.Len Stephens described the purification, cloning, and
characterization of a novel Rac GEF, which his group John York reviewed his lab’s ongoing experiments
implicating Ipk2p and one or both of its products, IP4has named P-Rex-1 (Welch et al., 2002). P-Rex-1 is regu-
lated by both PtdIns(3,4,5)P3 and G subunits and thus and IP5, as playing an important role in the regulation
of gene transcription (Odom et al., 2000). Their dataprovides a potential mechanism for signal integration
between multiple upstream pathways. suggest that the Ipk2p protein but not kinase activity is
necessary for assembly of the Arg80p-Mcm1p-Arg81pHeidi Welch, working in the joint laboratory group of
Stephens and Phill Hawkins, found that addition of PI transcription factor complex on the DNA. The kinase
activity to generate IP4 and IP5 is required for transcrip-3-kinase and G subunits to neutrophil lysates syner-
gistically stimulates superoxide formation. Further, they tion of the target genes. Again, the detailed mechanism
remains uncertain.found that the addition of PtdIns(3,4,5)P3-containing
vesicles alone stimulated the production of reactive oxy- The above work suggests a role for soluble inositol
polyphosphates in regulating nuclear events. A numbergen species and that this stimulation was inhibited by
the addition of dominant-negative N17-Rac. Finally, re- of groups also presented work hinting at a role for lipid-
bound phosphoinositides in the nucleus. Jeremyactive oxygen formation was stimulated in a wortman-
nin-resistant manner by the addition of either G sub- Thorner presented evidence for distinct roles for the PI
4-kinase Pik1 in the cytoplasm and nucleus in yeast.units or activated Rac-GTPS. These data led to a model
in which parallel pathways acting through PI 3-kinase First, he demonstrated that a GFP-Pik1 fusion or myc
epitope-tagged Pik1 can be detected in the nucleus.and G subunits activate Rac.
Dr. Stephens’ group began searching for a protein Next, like Susan Wente, he described experiments to
determine whether Pik1 tethered in the cytoplasm couldthat would activate Rac in a PtdIns(3,4,5)P3-depen-
dent manner. Assaying blood fractions for the ability to rescue a Pik1 deficiency. Intriguingly, when tethered to
the plasma membrane by fusion to a CAAX box, Pik1activate Rac only in the presence of exogenous
PtdIns(3,4,5)P3 led to the isolation of P-Rex-1, a large was unable to rescue a Pik1 deficiency. However, a Pik1
mutant 10-192 that localized purely to the nucleus butprotein with multiple domains that is highly expressed
in leukocytes. Among the domains of P-Rex-1 are a PH not to the cytoplasm also could not rescue a Pik1 defi-
ciency. Importantly, coexpressing the exclusively cyto-domain, a GEF domain, and an inositol polyphosphate
4-phosphatase domain. The full-length protein binds to plasmic and exclusively nuclear mutants of Pik1 does
rescue a Pik1 deficiency, arguing that Pik1 has requiredPtdIns(3,4,5)P3 and activates exchange of guanine nu-
cleotides on Rac1, Rac2, and Cdc42 in vitro. Further- functions in both compartments. The nature of these
distinct functions remains unclear.more, the Stephens group showed that PtdIns(3,4,5)P3
and G subunits synergistically activate the GEF activ- There were also examples of research suggesting a
role for lipid-bound phosphoinositides in the nucleus inity of P-Rex-1. Finally, overexpression of P-Rex-1 in-
duces lamellipodia formation, indicative of Rac activa- mammalian cells. Richard Anderson provided evidence
that PIPK1 and PIPKII may be found in the nucleustion, in a PI 3-kinase-dependent manner.
(Boronenkov et al., 1998). Although many questions re-
main concerning these observations, they suggest novelPhosphoinositides in the Nucleus
roles for phosphoinositides in the nucleus.A pervasive theme at the meeting was data hinting at a
role for phosphoinositides in the nucleus. To set the
stage, Susan Wente and John York summarized their PI 3-kinase as a Drug Target
One theme explored by a number of talks and posterspast and ongoing genetic and biochemical experiments
supporting a role for soluble inositol polyphosphates in was the importance of the PI 3-kinase pathway in human
pathophysiology and, therefore, interest in it as a drugthe regulation of RNA transcription and export from the
nucleus. Susan Wente reviewed her laboratory’s genetic target. Dr. Cantley reviewed evidence implicating PI
3-kinase in the development of cancer. First, he re-screen in S. cerevisiae to identify synthetic lethals in a
strain mutated in the gene for the mRNA export factor viewed the role of PI 3-kinase in promoting cell prolifera-
tion, cell motility, and anchorage-independent survival,Gle1p. The screen unexpectedly identified the genes
for phospholipase C and two novel inositol phosphate all important features of a metastatic cancer. He also
reviewed the many oncogenes that have been con-kinases, Ipk1p and Ipk2p (York et al., 1999). Yeast Ipk2p
is required to convert IP3 to IP4 and IP5, while Ipk1p is nected to the PI 3-kinase pathway, including early exper-
iments identifying PI 3-kinase as a target of the polyomarequired to convert IP5 to IP6. Wente’s group believes
that IP6 is the crucial product required for nuclear pore middle T-transforming antigen and the identification of
the protooncogenes AKT, myc, and cyclin D as down-function. An Ipk2p-GFP fusion protein localizes to the
nucleus (Odom et al., 2000), and an epitope-tagged stream targets of the PI 3-kinase pathway. More re-
cently, PTEN has been shown to function as a humanIpk1p localizes to the nucleus and perinuclear cyto-
plasm. However, Dr. Wente went on to show that the tumor suppressor gene by antagonizing the PI 3-kinase
pathway.nuclear localization of Ipk1p may not be required for
its function. A version of Ipk1p tethered to the plasma The role of PI 3-kinase in signaling downstream of the
insulin receptor has been long appreciated. However,membrane by fusion to Ste2p is capable of rescuing a
gle1-2 ipk1-4 synthetic lethal. This correlates with her Dr. Cantley reviewed the surprising and intriguing results
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SHIP-2, binds filamin and regulates submembraneous actin. J. Cellfrom his lab that mice deficient for either the p85 or
Biol. 155, 1065–1079.p85 regulatory subunits of PI 3-kinase exhibit in-
Fruman, D.A., Mauvais-Jarvis, F., Pollard, D.A., Yballe, C.M., Brazil,creased insulin sensitivity (Fruman et al., 2000; Mauvais-
D., Bronson, R.T., Kahn, C.R., and Cantley, L.C. (2000). Hypoglycae-Jarvis et al., 2002; Ueki et al., 2002). More investigation
mia, liver necrosis and perinatal death in mice lacking all isoforms
will be needed to provide a satisfactory mechanistic of phosphoinositide 3-kinase p85 alpha. Nat. Genet. 26, 379–382.
explanation for these unexpected results. Nevertheless, Kim, S.A., Taylor, G.S., Torgersen, K.M., and Dixon, J.E. (2002).
it is clear that pharmaceuticals that target the PI 3-kinase Myotubularin and MTMR2, phosphatidylinositol 3-phosphatases
pathway may be valuable reagents in the treatment of mutated in myotubular myopathy and type 4B Charcot-Marie-Tooth
disease. J. Biol. Chem. 277, 4526–4531.some cancers and, possibly, diabetes mellitus.
Accordingly, a number of groups presented posters Mauvais-Jarvis, F., Ueki, K., Fruman, D.A., Hirshman, M.F., Saka-
moto, K., Goodyear, L.J., Iannacone, M., Accili, D., Cantley, L.C.,demonstrating their progress in developing novel PI
and Kahn, C.R. (2002). Reduced expression of the murine p85alpha3-kinase assays amenable to high-throughput drug
subunit of phosphoinositide 3-kinase improves insulin signaling andscreens. Kinji Fuchikami et al. of Bayer, Henric Olsson
ameliorates diabetes. J. Clin. Invest. 109, 141–149.
et al. of Astra-Zeneca, Alexander Gray et al. of the Uni-
Odom, A.R., Stahlberg, A., Wente, S.R., and York, J.D. (2000). A
versity of Dundee, and Beth Drees et al. of Echelon all role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional
presented work showing progress in this area. Each control. Science 287, 2026–2029.
of these groups has developed assays that detect the Scheid, M.P., Huber, M., Damen, J.E., Hughes, M., Kang, V., Neilson,
binding of a soluble short chain PtdIns(3,4,5)P3 to a spe- P., Prestwich, G.D., Krystal, G., and Duronio, V. (2002). Phosphatidyl-
inositol(3,4,5)P3 is essential but not sufficient for PKB activation:cific protein domain. For example, Olsson et al. utilize
phosphatidylinositol(3,4)P2 is required for PKB phosphorylation atthe Grp1-PH domain to bind specifically to PtdIns(3,4,5)P3
Ser473. Studies using cells from SHIP/ knockout mice. J. Biol.and use Packard Bioscience’s proprietary AlphaScreen
Chem. 7, 7.
technology to detect the binding interaction. The differ-
Ueki, K., Yballe, C.M., Brachmann, S.M., Vicent, D., Watt, J.M., Kahn,ent groups use different readouts but employ similar
C.R., and Cantley, L.C. (2002). Increased insulin sensitivity in mice
principles. Echelon has been pivotal in developing and lacking p85beta subunit of phosphoinositide 3-kinase. Proc. Natl.
commercializing technologies to assist research in the Acad. Sci. USA 99, 419–424.
field, and they voiced their intention to market their new Welch, H.C.E., Coadwell, J., Ellson, C.D., Ferguson, G.J., Andrews,
PI 3-kinase assays as well. So far none of the groups S.R., Erdjument-Bromage, H., Tempst, P., Hawkins, P.T., and Ste-
phens, L. (2002). P-Rex1, a PtdIns(3,4,5)P3- and G-regulated gua-have presented new small molecule modulators of PI
nine nucleotide exchange factor for Rac. Cell 108, 809–821.3-kinase, but, of course, these are anxiously awaited as
York, J.D., Odom, A.R., Murphy, R., Ives, E.B., and Wente, S.R.novel research tools.
(1999). A phospholipase C-dependent inositol polyphosphate kinase
pathway required for efficient messenger RNA export. Science 285,
Conclusions 96–100.
The above excerpts illustrate only the tip of the iceberg
of exciting advances in lipid research presented at this
year’s Keystone Symposium on Lipid Mediators. Impor-
tantly, the collegial nature of the meeting fostered the
free exchange of ideas at all levels. Undoubtedly, this
meeting on the snowy slopes of Taos has produced an
avalanche of new ideas in lipid research.
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